Ken Griffin Viracta Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,900 shares of VIRX stock, worth $3,362. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,900
Previous 1,100
436.36%
Holding current value
$3,362
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding VIRX
# of Institutions
43Shares Held
9.39MCall Options Held
5.9KPut Options Held
0-
Bvf Inc San Francisco, CA3.61MShares$2.06 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.16MShares$661,9290.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$393,1340.22% of portfolio
-
Laurion Capital Management LP New York, NY420KShares$239,6420.0% of portfolio
-
Mai Capital Management364KShares$207,5350.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $21.4M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...